KHKirsi-Maria Haapasalo-Pesu

Kirsi-Maria Haapasalo-Pesu

*This is an algorithmically generated author record based on publicly available information.

Kirsi-Maria Haapasalo-Pesu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Simo Saarijärvi

    Adolescent Psychiatry Clinic VSSP, Department of Adolescent Psychiatry, University of Turku , Turku , Finland

    3 shared publications
  • Ritva Erkolahti

    2 shared publications
  • Veikko Aalberg

    2 shared publications
  • Liisa Lahelma

    Linja 13 B 20, FIN-00530 Helsinki, Finland

    1 shared publication
  • Marko Sorvaniemi

    1 shared publication
  • Mauri Marttunen

    Department of Adolescent Psychiatry, Helsinki University Hospital, Peijas Hospital Sairaalankatu 1, FIN-01400 Vantaa, Finland and Department of Mental Health and Alcohol Research National Public Health Institute, Helsinki, Finland and University of Oulu

    1 shared publication

Latest Publications

  • Open Access

    The Growing Trend of Prescribing Antipsychotics for Young People in Finland, 2000 to 2010

    by Kirsi-Maria Haapasalo-Pesu, Max Karukivi, Simo Saarijärvi

    Background: According to previous reports from many countries (e.g., the United States, Germany, the United Kingdom), the use of antipsychotic drugs has increased among young people. Antipsychotics have also increasingly been prescribed for non-psychotic disorders. Objective: The purpose of this study was to estimate the rate at which antipsychotics were prescribed for young people in the age groups of 10 to 14 years, 15 to 19 years, and 20 to 24 years in Finland in the years 2000, 2005, and 2010. Methods: This was a nationwide register study using data from the databases of Statistics Finland and the Finnish National Prescription Register. Statistics Finland’s databases provided background information, including the total number of young people and the Finnish National Prescription Register keeps record of all drug orders reimbursed by the Social Insurance Institution of Finland. Results: The prescription of antipsychotics grew 6.8-, 4.6-, and 2.6-fold over the study period for these three age groups, respectively. For the youngest age group, use was more common among males than females in all three periods studied. During the course of the study period, the use of antipsychotics became more common among females: in 2010, antipsychotics were more commonly used among females than males in both the 15- to 19-year-old age group and the 20- to 24-year-old age group. The younger the patient, the higher the probability that the indication for medication was a non-psychotic disorder. Conclusions: In Finland, the trends involved in the prescription of antipsychotic medications resemble those seen in many Western countries. Therefore, it is important that the safety and effectiveness of these pharmaceuticals be investigated among young people as well.


    • 1 January 2012
      • Vol. 128  (22) , 2319-25

    [Sleep disorders among adolescents--a major problem in mental health care].

    by Kirsi-Maria Haapasalo-Pesu, Max Karukivi

    Sleep disturbances are common in adolescents. The etiologies include biological, environmental, and sociocultural factors. The structure of sleep changes during adolescence, and it is easy for adolescents to stay awake. Sleep deprivation causes psychiatric symptoms. On the other hand, many psychiatric disorders cause secondary insomnia. The primary care is sleep hygiene counselling and behavioural therapy. If the sleep disorder is secondary, treatment of the primary disorder is the most important help. The scientific data of pharmacological management of insomnia of adolescent is thin. Melatonin might be worth a try, since there is scientific data of its effectiveness and safety.

  • Prescription of psychotropic drugs in adolescent psychiatry wards in Finland

    by Kirsi–Maria Haapasalo–Pesu, Ritva Erkolahti, Simo Saarijarvi, Veikko Aalberg

    This point–prevalence study was designed to assess adolescent psychiatrists’ practices of prescribing psychotropic drugs in hospital settings, and to compare the practices between the years 1991 and 1999. Data on patients’ gender, age, diagnosis and psychotropic medication were obtained by means of a questionnaire sent to four hospital units in Finland. The sample represented 49 % in 1991 and 29% in 1999 of all adolescent psychiatric inpatient beds in Finland. Of the patients included in the study, 30 % (20/66) in 1991 and 68 % (53/78) in 1999 were treated with drugs. The increase was biggest in the proportion of depressive patients and in the proportion of depressive patients receiving drugs. The results of this study suggest that the use of medication may have increased in recent years as new antidepressants and atypical neuroleptics have become available. Prescribing practices appeared to be appropriate, on the understanding that drug therapies are adjunct to other interventions


  • Mirtazapine in the Treatment of Adolescents with Major Depression: An Open-Label, Multicenter Pilot Study

    by Kirsi-Maria Haapasalo-Pesu, Tapani Vuola, Liisa Lahelma, Mauri Marttunen

    This multicenter, open-label study with a duration of 85 days was performed to evaluate the antidepressant efficacy and safety of mirtazapine (dose range, 30–45 mg) in 12–18-year-old adolescents diagnosed with major depression. Twenty-four (24) patients (15 female patients and 9 male patients) meeting the DSM-IV criteria for major depression and the Hamilton Rating Scale for Depression (HAM-D-17) score of 18 at baseline were enrolled in the study. The primary outcome measures were HAM-D-17, Beck Depression Inventory (BDI), and Clinical Global Impression (CGI) scales. Any changes in symptoms of anxiety were measured using the Hamilton Anxiety Rating Scale (HAM-A). The average age of the 23 subjects, who were eligible for analysis, was 16.3 years (standard deviation (SD) 6.11, median 17.3). The mean daily dose of mirtazapine was 32.9 mg. Mirtazapine showed a marked efficacy on all rating scales and was well tolerated. Mirtazapine had a beneficial effect on sleep. A rapid onset of sleep and pattern of action was seen. No dropouts due to adverse events were recorded. The most common treatment-emergent adverse events were tiredness, increased appetite, and dizziness. The results of this study suggest that mirtazapine may be an effective treatment for major depression in adolescents.


  • Prescription of psychotropic drugs in adolescent psychiatry wards in Finland

    by Kirsi-Maria Haapasalo-Pesu, Ritva Erkolahti, Simo Saarijärvi, Veikko Aalberg

    This point-prevalence study was designed to assess adolescent psychiatrists' practices of prescribing psychotropic drugs in hospital settings, and to compare the practices between the years 1991 and 1999. Data on patients' gender, age, diagnosis and psychotropic medication were obtained by means of a questionnaire sent to four hospital units in Finland. The sample represented 49% in 1991 and 29% in 1999 of all adolescent psychiatric inpatient beds in Finland. Of the patients included in the study, 30% (20/66) in 1991 and 68% (53/78) in 1999 were treated with drugs. The increase was biggest in the proportion of depressive patients and in the proportion of depressive patients receiving drugs. The results of this study suggest that the use of medication may have increased in recent years as new antidepressants and atypical neuroleptics have become available. Prescribing practices appeared to be appropriate, on the understanding that drug therapies are adjunct to other interventions.


  • National prescribing practices of adolescent psychiatrists for psychotropic medications in outpatient care in Finland

    by Kirsi-Maria Haapasalo-Pesu, Simo Saarijärvi, Marko Sorvaniemi

    We studied national prescribing practices for psychotropic drugs in adolescent psychiatric outpatient care in Finland in the cross-sectional survey study in 1999. A questionnaire was sent to the adolescent psychiatrists employed in the community outpatient clinics covering all Finland. The response rate was 81% (n=34). On average, the respondents reported that 33% of their outpatients were treated with drugs. Selective serotonin reuptake inhibitors (SSRIs) were the drug of choice in the treatment of depression and obsessive-compulsive disorder (OCD). Atypical antipsychotics played an important role in the treatment of psychotic adolescents. Adolescent psychopharmacology is an important and developing part of treatment of mentally disordered young people, on the understanding that drug therapies are adjunct to other treatment interventions.


  • Olanzapine induces remarkable weight gain in adolescent patients

    by K.-M. Haapasalo-Pesu, S. Saarijärvi

    We present here clinical case reports of three adolescents, aged 14–17 years, who were treated with olanzapine. The daily dose was 10 mg. Prior to olanzapine, the patients were unsuccessfully treated with other antipsychotic drugs. The response to olanzapine for psychotic symptoms was clinically significant in all three patients. The major adverse effect was excessive weight gain. The increases in body mass index (BMI) were 9, 8 and 5 kg/m2. One of the patients later lost the additional weight. Especially in adolescents obesity is a serious side effect and potential consequences include numerous health problems.